By Fineline Cube 
Bristol-Myers Squibb Co. (BMS, NYSE: BMY) announced that the European Commission (EC) has granted marketing approval for Opdivo (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult and adolescent patients aged 12 years and older with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | European Commission (EC) |
| Approval Type | Full marketing authorization |
| Product | Opdivo (nivolumab) + AVD chemotherapy |
| Indication | First-line treatment of Stage III/IV classical Hodgkin Lymphoma |
| Patient Population | Adults and adolescents ≥12 years |
| Approval Date | 1 Jun 2026 |
Drug Profile & Mechanism of Action
- Molecule: Opdivo (nivolumab) – programmed death-1 (PD-1) immune checkpoint inhibitor
- Combination: Standard AVD chemotherapy regimen (doxorubicin, vinblastine, dacarbazine)
- Innovation: First PD-1 inhibitor approved in Europe as part of a first-line combination therapy for advanced cHL
- Intellectual Property: Patents held by Bristol-Myers Squibb covering nivolumab composition and specific combination uses
Clinical Evidence – Phase III SWOG 1826 Trial
| Endpoint | Result (Opdivo+AVD) | Comparator (Brentuximab+AVD) | Relative Benefit |
|---|---|---|---|
| Progression-Free Survival | Not reached (median) | Not reached (median) | 58% reduction in risk of progression or death |
| Follow-up Period | 13.7 months (median) | 13.7 months (median) | Statistically significant improvement |
| Primary Endpoint | Met with statistical significance | — | p-value <0.001 |
| Safety | Consistent with known profiles of individual agents | — | Manageable safety profile |
The international Phase III SWOG 1826 trial (Study CA2098UT) enrolled patients across multiple countries and demonstrated superior efficacy of the Opdivo-AVD combination compared to brentuximab vedotin plus AVD.
Market Impact & Outlook
- European cHL Landscape: Approximately 3,000-4,000 new advanced-stage cHL cases diagnosed annually across EU markets
- Revenue Forecast: Analysts project peak annual sales of €350-450 million for this indication, representing approximately 8-10% growth to Opdivo’s current European revenue
- Competitive Edge: The substantial PFS benefit positions Opdivo-AVD as a potential new standard of care for first-line advanced cHL treatment in Europe
- Strategic Implications: Strengthens BMS’s immuno-oncology portfolio in hematologic malignancies and extends Opdivo’s market exclusivity timeline
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial expectations for Opdivo. Actual results may differ due to risks including market adoption, reimbursement decisions, and competitive dynamics.-Fineline Info & Tech